CAJ | 학술논문

目的：检测糖原合成酶激酶3β（ GSK3β）、p-GSK3βser9和p-GSK3βTyr216表达水平在宫颈癌组织中的表达情况及其与临床病理因素的相关性。方法收集2012年1月至2014年12月间第四军医大学西京医院妇产科收治的宫颈鳞癌病理标本80例，采用免疫组化SP法对宫颈癌组织中GSK3β、p-GSK3βser9和p-GSK3βTyr216表达水平进行检测，并分析GSK3β、p-GSK3βser9和p-GSK3βTyr216表达与临床病理因素之间关系。结果宫颈癌组织中GSK3β、p-GSK3βser9和p-GSK3βTyr216表达阳性率分别为18．8％、68．8％和12．5％。早期宫颈癌患者中GSK3β和p-GSK3βTyr216表达显著高于中晚期宫颈癌患者（25．5％ vs．4．0％，χ2＝5．193，P＝0．029；76．4％vs 52．0％，χ2＝4．749，P＝0．039），早期宫颈癌患者中p-GSK3βser9表达显著低于中晚期宫颈癌患者（5．5％vs．28．0％，χ2＝7．988，P＝0．009）。在宫颈癌组织中随着细胞学分级的降低，p-GSK3βser9阳性率也随之升高（7．4％、7．9％和33．3％，χ2＝7．329，P＝0．031）。淋巴结转移阳性的宫颈癌患者中GSK3β和p-GSK3βTyr216表达均显著低于淋巴结转移阴性的宫颈癌患者（5．9％vs．28．3％，χ2＝6．427，P＝0．018；52．9％vs．80．4％，χ2＝6．878，P＝0．014），p-GSK3βser9在淋巴结转移阳性的宫颈癌患者中表达显著高于淋巴结转移阴性的宫颈癌患者（23．5％vs．4．3％，χ2＝6．577，P＝0．015）。结论宫颈癌组织中GSK3β、p-GSK3βser9和p-GSK3βTyr216表达与宫颈癌临床分期、细胞学分级和淋巴结转移相关，提示GSK3β基因可能在宫颈癌组织发生发展中发挥重要作用。
목적：검측당원합성매격매3β（ GSK3β）、p-GSK3βser9화p-GSK3βTyr216표체수평재궁경암조직중적표체정황급기여림상병리인소적상관성。방법수집2012년1월지2014년12월간제사군의대학서경의원부산과수치적궁경린암병리표본80례，채용면역조화SP법대궁경암조직중GSK3β、p-GSK3βser9화p-GSK3βTyr216표체수평진행검측，병분석GSK3β、p-GSK3βser9화p-GSK3βTyr216표체여림상병리인소지간관계。결과궁경암조직중GSK3β、p-GSK3βser9화p-GSK3βTyr216표체양성솔분별위18．8％、68．8％화12．5％。조기궁경암환자중GSK3β화p-GSK3βTyr216표체현저고우중만기궁경암환자（25．5％ vs．4．0％，χ2＝5．193，P＝0．029；76．4％vs 52．0％，χ2＝4．749，P＝0．039），조기궁경암환자중p-GSK3βser9표체현저저우중만기궁경암환자（5．5％vs．28．0％，χ2＝7．988，P＝0．009）。재궁경암조직중수착세포학분급적강저，p-GSK3βser9양성솔야수지승고（7．4％、7．9％화33．3％，χ2＝7．329，P＝0．031）。림파결전이양성적궁경암환자중GSK3β화p-GSK3βTyr216표체균현저저우림파결전이음성적궁경암환자（5．9％vs．28．3％，χ2＝6．427，P＝0．018；52．9％vs．80．4％，χ2＝6．878，P＝0．014），p-GSK3βser9재림파결전이양성적궁경암환자중표체현저고우림파결전이음성적궁경암환자（23．5％vs．4．3％，χ2＝6．577，P＝0．015）。결론궁경암조직중GSK3β、p-GSK3βser9화p-GSK3βTyr216표체여궁경암림상분기、세포학분급화림파결전이상관，제시GSK3β기인가능재궁경암조직발생발전중발휘중요작용。
Objective To investigate the expressions of glycogen synthase kinase 3β( GSK3β) , p-GSK3βser9 and p-GSK3βTyr216 in cervical carcinoma and their correlation with clinical pathological factors.Methods By using immunohistochemistry, GSK3β, p-GSK3βser9 and p-GSK3βTyr216 protein expressions were detected in 80 cases of cervical carcinoma admitted in Xijing Hospital of Fourth Military Medical University during January 2012 to December 2014.The correlations between expressions of GSK3β, p-GSK3βser9 and p-GSK3βTyr216 and clinicopathological factors were analyzed.Results The positive expression rates of GSK3β, p-GSK3βser9 and p-GSK3βTyr216 in cervical carcinoma were 18.8%, 68.8% and 12.5%, respectively.The expressions of GSK3βand p-GSK3βTyr216 in early stage group were significantly higher than those in advanced stage group (25.5%vs 4.0%, χ2 =5.193,P=0.029;76.4% vs 52.0%,χ2 =4.749,P=0.039), but the expression rate of p-GSK3βser9 was obviously lower (5.5%vs 28.0%,χ2 =7.988,P=0.009).The positive expression rates of p-GSK3βser9 in well and moderately differentiated tumors were lower than those in poorly differentiated tumors (7.4%, 7.9%and 33.3%,χ2 =7.329, P=0.031).The expressions of GSK3βand p-GSK3βTyr216 were significantly lower in patients with positive lymph node metastasis than in those with negative lymph node status (5.9%vs 28.3%,χ2 =6.427,P=0.018;52.9%vs 80.4%,χ2 =6.878, P=0.014), but the expression of p-GSK3βser9 was higher in patients with lymph node metastases (23.5% vs 4.3%, χ2 =6.577,P=0.015) .Conclusion The expressions of GSK3β, p-GSK3βser9 and p-GSK3βTyr216 in cervical carcinoma are correlated with clinical TNM staging, histological grades and lymph node metastases, which suggests that GSK3βmay play a potential role in cervical tumor genesis.